Aurobindo Pharma launches Adquey in US market

Aurobindo Pharma Limited

has launched Adquey ointment in the US through its subsidiary Acrotech Biopharma. The launch marks Acrotech’s entry into the US dermatology market. Aurobindo has also established a dedicated dermatology business unit to support the new product and build the segment. The launch adds another therapeutic area to the company’s US portfolio. However, the financial impact will depend on prescription volumes, market adoption and the competitive environment. What I’m watching: Initial sales contribution from Adquey, further dermatology launches and the company’s US product pipeline. Stance: Tracking execution and commercial uptake following the US launch. Disclosure: This post is for educational purposes only and is not investment advice or a buy/sell recommendation. Disclose any holding or interest before publishing.